Building on our experience in lung disease, our goal is to take lung cancer on, transform the treatment landscape and ultimately, redefine all lung cancers as curable.
Pioneering New Medicines Through External Innovation
On 22 November 2024 Boehringer Ingelheim hosted the event “Unleashing Innovation at Boehringer Ingelheim: Pioneering New Medicines Through External Innovation” at the Institute of Molecular Pathology (IMP)
At Boehringer Ingelheim, we are investing into the power of computational biology and data sciences to accelerate the journey from scientific discoveries to breakthrough therapies.
Boehringer Ingelheim RCV provides over six million patients with innovative therapies. Ensuring that the patients’ needs at every stage are met precisely is of decisive importance.
Powerful teams are very often diverse. A good mixture of different personalities is beneficial, and it is for this reason that diversity in general has been encouraged for years at Boehringer Ingelheim.